Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age \>16 weeks (determined by LMP and fundal height)- if there is discordance between the two, the more conservative estimate (i.e. lower) will be used, to prevent accidental exposure of a 1st trimester fetus~2. Normal fetal heart beat detected by Doppler~3. Presence of any P. falciparum parasitemia ≤ 50,000 parasites/microliter (thick film)~4. Willing to sign or thumb print informed consent~5. Willing to return for scheduled follow up visits for treatment and observation until delivery~6. Willing to deliver in health facility~Exclusion Criteria:~1. Pregnancy \< 16 weeks~2. Microscopically confirmed P. vivax or mixed infection/ parasitemia (P. falciparum and another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae)~3. History of allergy or hypersensitivity to interventional drugs~4. Exposure to antimalarial drugs and other drugs with antimalarial activity within the past 2 months, as determined by history from the woman (quinine, mefloquine, or artemisinin derivatives, including AL and MA)~5. Patients taking drugs with possible interaction with study drugs (ie. warfarin, digoxin)~6. History or family history of epilepsy or psychiatric disorder~7. Presence of signs and symptoms of severe malaria~8. Hemoglobin \< 7 g/dl~9. Inability to tolerate oral medication (repeated vomiting, impairment of consciousness).~10. History of chronic disease including diabetes, renal failure, hepatic failure, heart disease requiring anti-arrhythmic drugs or warfarin, HIV or AIDS, known hemoglobinopathy~11. Participant's inability to return for follow up visits~12. Age \<15 years

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mefloquine- Artesunate (Type: EXPERIMENTAL): Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
- Artemether- Lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal

Based on this trial design, predict the completion outcome and termination type (if applicable).